Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Patients (pts) with polycythemia vera (PV) suffer from pruritus, night sweats, and other symptoms, as well as from thromboembolic complications and progression to post-PV myelofibrosis. Ruxolitinib (RUX) is approved for second-line therapy in high-risk PV pts with hydroxyurea intolerance or resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Koschmieder, Steffen, Isfort, Susanne, Wolf, Dominik, Heidel, Florian H., Hochhaus, Andreas, Schafhausen, Philippe, Griesshammer, Martin, Wolleschak, Denise, Platzbecker, Uwe, Döhner, Konstanze, Jost, Philipp J., Parmentier, Stefani, Schaich, Markus, von Bubnoff, Nikolas, Stegelmann, Frank, Maurer, Angela, Crysandt, Martina, Gezer, Deniz, Kortmann, Maike, Franklin, Jeremy, Frank, Julia, Hellmich, Martin, Brümmendorf, Tim H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889492/
https://www.ncbi.nlm.nih.gov/pubmed/36564535
http://dx.doi.org/10.1007/s00277-022-05080-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889492/
https://www.ncbi.nlm.nih.gov/pubmed/36564535
http://dx.doi.org/10.1007/s00277-022-05080-7

Ejemplares similares